Immix Biopharma, Inc.
NASDAQ Capital MarketTotal Valuation
Immix Biopharma, Inc. carries a market capitalization of 526.61M, placing it among publicly traded companies globally. Its enterprise value stands at 502.86M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 526.61M |
| Enterprise Value | 502.86M |
Share Statistics
Immix Biopharma, Inc. currently has 71.19M shares outstanding.
| Shares Outstanding | 71.19M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 3.21 |
| P/TBV Ratio | 3.21 |
| P/FCF Ratio | -13.70 |
| P/OCF Ratio | -13.49 |
Financial Position
Immix Biopharma, Inc. maintains a current ratio of 25.13, meaning it holds 25.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 25.13 |
| Quick Ratio | 24.95 |
| Debt / Equity | 0.44 |
| Debt / EBITDA | -0.02 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -34.18 |
| Return on Assets (ROA) | -31.34 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 33,310.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Immix Biopharma, Inc.'s stock has gained approximately 369.90291% over the past 52 weeks. The 50-day moving average sits at 11.58, while the 200-day moving average is 9.13.
| Beta (5Y) | N/A |
| 52-Week Price Change | 369.90291% |
| 50-Day Moving Average | 11.58 |
| 200-Day Moving Average | 9.13 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -41.33M, while operating income came in at -41.82M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -41.82M |
| Pretax Income | -39.88M |
| Net Income | -39.92M |
| EBITDA | -41.33M |
| EBIT | -41.82M |
| Earnings Per Share (EPS) | -0.79 |
Balance Sheet
Immix Biopharma, Inc. holds 232.11M in cash and equivalents against 1.00M in total debt, resulting in a net debt position of -225.49M. Total book value stands at 228.92M, with working capital of 224.49M providing operational flexibility.
| Cash & Cash Equivalents | 232.11M |
| Total Debt | 1.00M |
| Net Debt | -225.49M |
| Equity (Book Value) | 228.92M |
| Book Value Per Share | 3.22 |
| Working Capital | 224.49M |
Cash Flow
Immix Biopharma, Inc. produced -38.50M in operating cash flow over the past twelve months. After subtracting -591,111.00 in capital expenditures, free cash flow totaled -39.09M - equivalent to -0.78 per share.
| Operating Cash Flow | -38.50M |
| Capital Expenditures | -591,111.00 |
| Free Cash Flow | -39.09M |
| FCF Per Share | -0.78 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -35.63 |
| FCF Yield | -7.30 |
Scores
Immix Biopharma, Inc. posts an Altman Z-Score of 43.02, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 43.02 |